The Lighthouse Tenofovir Cohort Study (LighTen)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02381275|
Recruitment Status : Recruiting
First Posted : March 6, 2015
Last Update Posted : March 6, 2015
Lighthouse, in cooperation with the University Heidelberg Public Health Institute and the University Köln (Cologne) would like to set up a cohort to study baseline characteristics and long-term clinical outcomes of patients using Tenofovir based Antiretroviral Therapy at the Lighthouse. As of March 2014, patients above 18 years and giving informed consent coming to the Lighthouse to newly initiate ART will be approached to enroll in the cohort.
The results will be disseminated both nationally at the Ministry of Health Technical Working Group (TWG), at the annual Research Dissemination and Best Practices conferences of the College of Medicine and National AIDS Commission as well as internationally. The results will also be written up for publication in appropriate peer-reviewed journals.
|Condition or disease||Intervention/treatment|
|Chronic Renal Disease||Drug: Tenofovir Disoproxil Fumarate|
The proposed observational cohort study will lead to improved identification of patients with virological failure and adverse drug effects, improved identification of relevant co-morbidities and result in better individual management. More importantly however, the results will allow estimates for the proportion of the described complications in the overall Malawian treatment cohort. This claim can be exemplified by the retrospective analysis of patients at the Lighthouse who were switched from the new 5A regimen to 6 A regimen as a result of adverse effects of Efavirenz.
The aim of this study is to describe baseline clinical characteristics and long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics. The specific objectives are outlined below:
Objective 1: To determine the prevalence of renal dysfunction at enrolment and during follow-up among adult HIV-infected individuals starting ART.
Objective 2: To determine the prevalence of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections among adult HIV-infected individuals starting ART and during treatment follow-up.
Objective 3: To determine the prevalence of non-communicable co-morbidities during treatment follow-up of HIV-infected individuals starting ARTand during treatment follow-up.
The study will take place at the Lighthouse, a tertiary referral ART centre, with over 25,000 patients, in Lilongwe, Malawi. Considering the study cost and power to detect a prevalence of 22% for renal impairment, we expect to have a convenience sample size of at least 850 patients at the end of three year follow-up period. The current retention at three years is almost 56%. Using this retention, we will therefore enrol almost 1,500 patients starting ART.
|Study Type :||Observational|
|Estimated Enrollment :||1500 participants|
|Official Title:||Baseline Characteristics and Long Term Clinical Outcomes of Patients Using Malawi's New First Line Antiretroviral Regimen at Lighthouse: The Lighthouse Tenofovir Cohort|
|Study Start Date :||August 2014|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||July 2018|
Drug: Tenofovir Disoproxil Fumarate
- Proportion of HIV-infected individuals with renal dysfunction [ Time Frame: 36 months post ART initiation ]Patients will be followed in the clinic up to 36 months
- Proportion of HIV-infected individuals with HIV/ HBV and HCV infections [ Time Frame: 36 months post ART initiation ]Patients will be followed in the clinic up to 36 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02381275
|Contact: Sam JP Phiri, PhD, MSc,||+265 1 758 940 ext email@example.com|
|Contact: Hannock M Tweya, MSc, BSc||+265 1 758 940 ext firstname.lastname@example.org|
|Lilongwe, Malawi, 0000|
|Contact: Thomas Chaweza, DCM +265 1 758 940 ext 236 email@example.com|
|Contact: Angellina Chinsinga, BSc +265 1 758 940 ext 231 firstname.lastname@example.org|